vs

Side-by-side financial comparison of Ametek (AME) and Edwards Lifesciences (EW). Click either name above to swap in a different company.

Ametek is the larger business by last-quarter revenue ($2.0B vs $1.6B, roughly 1.2× Edwards Lifesciences). Edwards Lifesciences runs the higher net margin — 23.1% vs 19.9%, a 3.1% gap on every dollar of revenue. On growth, Edwards Lifesciences posted the faster year-over-year revenue change (16.7% vs 13.4%). Over the past eight quarters, Edwards Lifesciences's revenue compounded faster (9.7% CAGR vs 7.3%).

AMETEK, Inc. is an American multinational conglomerate and global designer and manufacturer of electronic instruments and electromechanical devices with headquarters in the United States and over 150 sites worldwide.

Edwards Lifesciences Corporation is an American medical technology company headquartered in Irvine, California, specializing in artificial heart valves and hemodynamic monitoring. It developed the Sapien transcatheter aortic heart valve made of cow tissue within a balloon-expandable, cobalt-chromium frame, deployed via catheter.

AME vs EW — Head-to-Head

Bigger by revenue
AME
AME
1.2× larger
AME
$2.0B
$1.6B
EW
Growing faster (revenue YoY)
EW
EW
+3.3% gap
EW
16.7%
13.4%
AME
Higher net margin
EW
EW
3.1% more per $
EW
23.1%
19.9%
AME
Faster 2-yr revenue CAGR
EW
EW
Annualised
EW
9.7%
7.3%
AME

Income Statement — Q4 FY2025 vs Q1 FY2026

Metric
AME
AME
EW
EW
Revenue
$2.0B
$1.6B
Net Profit
$398.6M
$380.7M
Gross Margin
36.0%
78.0%
Operating Margin
25.3%
1.8%
Net Margin
19.9%
23.1%
Revenue YoY
13.4%
16.7%
Net Profit YoY
2.9%
6.8%
EPS (diluted)
$1.73
$0.66

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
AME
AME
EW
EW
Q1 26
$1.6B
Q4 25
$2.0B
$1.6B
Q3 25
$1.9B
$1.6B
Q2 25
$1.8B
$1.5B
Q1 25
$1.7B
$1.4B
Q4 24
$1.8B
$1.4B
Q3 24
$1.7B
$1.4B
Q2 24
$1.7B
$1.4B
Net Profit
AME
AME
EW
EW
Q1 26
$380.7M
Q4 25
$398.6M
$91.2M
Q3 25
$371.4M
$291.1M
Q2 25
$358.4M
$333.2M
Q1 25
$351.8M
$358.0M
Q4 24
$387.3M
$385.6M
Q3 24
$340.2M
$3.1B
Q2 24
$337.7M
$366.3M
Gross Margin
AME
AME
EW
EW
Q1 26
78.0%
Q4 25
36.0%
78.1%
Q3 25
36.3%
77.8%
Q2 25
35.8%
77.5%
Q1 25
36.1%
78.7%
Q4 24
36.6%
78.9%
Q3 24
36.0%
80.6%
Q2 24
36.0%
79.9%
Operating Margin
AME
AME
EW
EW
Q1 26
1.8%
Q4 25
25.3%
9.6%
Q3 25
25.8%
19.8%
Q2 25
26.0%
26.8%
Q1 25
26.3%
27.9%
Q4 24
26.6%
22.6%
Q3 24
26.1%
25.9%
Q2 24
25.8%
26.8%
Net Margin
AME
AME
EW
EW
Q1 26
23.1%
Q4 25
19.9%
5.8%
Q3 25
19.6%
18.7%
Q2 25
20.2%
21.7%
Q1 25
20.3%
25.3%
Q4 24
22.0%
27.8%
Q3 24
19.9%
226.7%
Q2 24
19.5%
26.7%
EPS (diluted)
AME
AME
EW
EW
Q1 26
$0.66
Q4 25
$1.73
$0.16
Q3 25
$1.60
$0.50
Q2 25
$1.55
$0.56
Q1 25
$1.52
$0.61
Q4 24
$1.67
$0.65
Q3 24
$1.47
$5.13
Q2 24
$1.45
$0.61

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
AME
AME
EW
EW
Cash + ST InvestmentsLiquidity on hand
$458.0M
Total DebtLower is stronger
$2.3B
Stockholders' EquityBook value
$10.6B
Total Assets
$16.1B
Debt / EquityLower = less leverage
0.21×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
AME
AME
EW
EW
Q1 26
Q4 25
$458.0M
$4.2B
Q3 25
$439.2M
$3.8B
Q2 25
$619.7M
$4.1B
Q1 25
$399.0M
$3.9B
Q4 24
$374.0M
$4.0B
Q3 24
$396.3M
$4.4B
Q2 24
$396.6M
$2.0B
Total Debt
AME
AME
EW
EW
Q1 26
Q4 25
$2.3B
Q3 25
Q2 25
Q1 25
Q4 24
$2.1B
Q3 24
Q2 24
Stockholders' Equity
AME
AME
EW
EW
Q1 26
Q4 25
$10.6B
$10.3B
Q3 25
$10.5B
$10.2B
Q2 25
$10.4B
$10.5B
Q1 25
$10.0B
$10.1B
Q4 24
$9.7B
$10.0B
Q3 24
$9.6B
$9.5B
Q2 24
$9.3B
$7.4B
Total Assets
AME
AME
EW
EW
Q1 26
Q4 25
$16.1B
$13.7B
Q3 25
$16.2B
$13.3B
Q2 25
$15.3B
$13.5B
Q1 25
$14.9B
$13.0B
Q4 24
$14.6B
$13.1B
Q3 24
$14.8B
$13.0B
Q2 24
$14.8B
$10.1B
Debt / Equity
AME
AME
EW
EW
Q1 26
Q4 25
0.21×
Q3 25
Q2 25
Q1 25
Q4 24
0.22×
Q3 24
Q2 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
AME
AME
EW
EW
Operating Cash FlowLast quarter
$584.3M
Free Cash FlowOCF − Capex
$527.3M
FCF MarginFCF / Revenue
26.4%
Capex IntensityCapex / Revenue
2.9%
Cash ConversionOCF / Net Profit
1.47×
TTM Free Cash FlowTrailing 4 quarters
$1.7B

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
AME
AME
EW
EW
Q1 26
Q4 25
$584.3M
$450.9M
Q3 25
$440.9M
$573.7M
Q2 25
$359.1M
$290.2M
Q1 25
$417.5M
$280.4M
Q4 24
$550.0M
$-127.5M
Q3 24
$487.2M
$351.8M
Q2 24
$381.4M
$371.5M
Free Cash Flow
AME
AME
EW
EW
Q1 26
Q4 25
$527.3M
$353.5M
Q3 25
$420.0M
$516.2M
Q2 25
$329.8M
$240.9M
Q1 25
$394.5M
$224.4M
Q4 24
$498.3M
$-177.3M
Q3 24
$460.9M
$299.9M
Q2 24
$360.0M
$286.1M
FCF Margin
AME
AME
EW
EW
Q1 26
Q4 25
26.4%
22.5%
Q3 25
22.2%
33.2%
Q2 25
18.5%
15.7%
Q1 25
22.8%
15.9%
Q4 24
28.3%
-12.8%
Q3 24
27.0%
22.1%
Q2 24
20.8%
20.9%
Capex Intensity
AME
AME
EW
EW
Q1 26
Q4 25
2.9%
6.2%
Q3 25
1.1%
3.7%
Q2 25
1.6%
3.2%
Q1 25
1.3%
4.0%
Q4 24
2.9%
3.6%
Q3 24
1.5%
3.8%
Q2 24
1.2%
6.2%
Cash Conversion
AME
AME
EW
EW
Q1 26
Q4 25
1.47×
4.94×
Q3 25
1.19×
1.97×
Q2 25
1.00×
0.87×
Q1 25
1.19×
0.78×
Q4 24
1.42×
-0.33×
Q3 24
1.43×
0.11×
Q2 24
1.13×
1.01×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

AME
AME

Transferred At Point In Time$1.1B54%
Electronic Instruments Group$620.1M31%
Transferred Over Time$294.6M15%

EW
EW

Segment breakdown not available.

Related Comparisons